Srt Fabry Galafold denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for srt fabry galafold are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Step Therapy to Galafold

Step therapy (also called "fail-first") requires that a patient try one or more preferred or lower-cost drugs before the insurer will cover the requested medication. For Galafold, Aetna may require documented use of or a clinical reason to skip enzyme replacement therapy (ERT) as a preceding step.

The challenge for Fabry disease is that Galafold and ERT are not interchangeable for all patients — Galafold is only appropriate for patients with amenable GLA mutations. A step-therapy requirement that mandates ERT for a patient who is a candidate for Galafold may be clinically inappropriate and therefore appealable on that basis.

## Federal Protections Against Inappropriate Step Therapy

Many states have enacted step-therapy override laws that require insurers to grant an exception when step therapy is clinically contraindicated or when the patient has already tried and had an inadequate response to the required step. Even in states without such laws, ACA §2719 external review gives you the right to have a clinician reviewer independent of Aetna assess whether the step-therapy requirement is appropriate for your specific situation. The external review window is approximately four months from the denial. Expedited review is available for urgent medical situations. ERISA §503 full-and-fair review applies to employer-sponsored plans.

## Grounds for a Step-Therapy Exception

The most direct path to overturning this denial is to establish one or more of the following:

• The required step drug is not medically appropriate: Galafold is only indicated for patients with amenable mutations. If the patient has an amenable mutation, document that the clinical rationale for Galafold over ERT rests on the mutation's amenability, not merely preference.
• Prior adequate trial of ERT: If the patient has already received ERT, provide infusion records with dates, clinical response notes, and any documented adverse reactions or inadequate clinical response.
• Clinical contraindication or intolerance: Chart documentation of any reason the required prior-step therapy cannot be used should be included even if it does not rise to a strict contraindication — tolerability issues, access barriers, and quality-of-life impacts are all relevant.

## Documentation to Gather

• Genetic sequencing report confirming the amenable GLA mutation, with amenability determination per the FDA-approved label
• Complete ERT treatment history (if applicable): dates, doses, clinical notes, outcomes
• Prescriber letter addressing each step-therapy criterion in Aetna's policy and explaining the clinical basis for the override request
• Aetna's published step-therapy criteria for Galafold (obtain from the provider portal)
• The FDA-approved prescribing label for Galafold, highlighting the amenable-mutation indication

Pair the prescriber letter with the criteria side-by-side mapping so the reviewer can confirm the exception grounds at a glance.